Biodexa Pharmaceuticals Plc (BDRX)
NASDAQ: BDRX · Real-Time Price · USD
5.04
-0.05 (-0.98%)
At close: Dec 5, 2025, 4:00 PM EST
6.49
+1.45 (28.77%)
After-hours: Dec 5, 2025, 7:59 PM EST
Biodexa Pharmaceuticals Employees
Biodexa Pharmaceuticals had 13 employees as of December 31, 2024. The number of employees decreased by 8 or -38.10% compared to the previous year.
Employees
13
Change (1Y)
-8
Growth (1Y)
-38.10%
Revenue / Employee
n/a
Profits / Employee
-$656,254
Market Cap
3.12M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
BDRX News
- 5 days ago - Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP - GlobeNewsWire
- 12 days ago - Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP - GlobeNewsWire
- 4 weeks ago - Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion - GlobeNewsWire
- 2 months ago - Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025 - GlobeNewsWire
- 3 months ago - Interim results for the six months ended June 30, 2025 - GlobeNewsWire
- 3 months ago - Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled - Accesswire
- 3 months ago - Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) - GlobeNewsWire
- 4 months ago - ADR Ratio Change Effective - GlobeNewsWire